A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide-Cephalosporin Heterodimer Gram-Positive Antibiotic, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2014
At a glance
- Drugs TD 1607 (Primary)
- Indications Gram-positive infections
- Focus Adverse reactions
- Sponsors Theravance
- 09 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History